-+ 0.00%
-+ 0.00%
-+ 0.00%
InflaRx’s Izicopan Reduces Kidney Injury in Preclinical Studies
Share
Listen to the news
InflaRx’s Izicopan Reduces Kidney Injury in Preclinical Studies
  • InflaRx presented preclinical results showing oral izicopan reduced kidney injury in hamster models at Kidney Week 2026 in Denver.
  • Treatment improved kidney function markers and tissue damage; reductions in kidney fibrosis were not statistically significant.
  • Structural modeling indicated potentially lower drug-interaction risk than avacopan, supporting izicopan’s development for complement-driven kidney diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610221200PRIMZONEFULLFEED9851392) on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending